{"id":227,"date":"2020-07-19T11:00:19","date_gmt":"2020-07-19T15:00:19","guid":{"rendered":"https:\/\/dev.mrctcenter.org\/diversity-in-clinical-research\/?page_id=227"},"modified":"2020-07-19T11:00:19","modified_gmt":"2020-07-19T15:00:19","slug":"diversity-leadership-and-workgroup","status":"publish","type":"page","link":"https:\/\/dev.mrctcenter.org\/diversity-in-clinical-research\/about\/diversity-leadership-and-workgroup\/","title":{"rendered":"Leadership and Workgroup"},"content":{"rendered":"

[vc_row css=”.vc_custom_1617045318104{padding-right: 50px !important;padding-left: 50px !important;}”][vc_column][vc_empty_space][vc_column_text css=”.vc_custom_1596633942903{padding-bottom: 150px !important;}”]\"\"A 50+-member, international, multi-stakeholder workgroup convened by the Multi-Regional Clinical Trials Center of Brigham and Women\u2019s Hospital and Harvard University (MRCT Center<\/a>) developed this Guidance Document and accompanying Toolkit<\/em>.\u00a0 While every member contributed to the development of the Diversity Framework<\/em>, the leadership of the MRCT Center is responsible for the final content.[\/vc_column_text][vc_separator border_width=”2″][vc_column_text]<\/p>\n

The views and findings expressed in this document are those of the authors and do not imply endorsement or reflect the views or policies of the U.S. Food and Drug Administration or the affiliated organization or entity of any member who contributed to this work. Individuals have served in their individual capacity.<\/em><\/h5>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row css=”.vc_custom_1617045330889{padding-right: 50px !important;padding-left: 50px !important;}”][vc_column][vc_tta_accordion style=”modern” spacing=”10″ gap=”10″ active_section=”0″ no_fill=”true” collapsible_all=”true”][vc_tta_section title=”Leadership team” tab_id=”1596393026817-c16005c1-161d”][vc_column_text]<\/p>\n

    \n
  • RADM Richardae Araojo, U.S. Food and Drug Administration (as of August 2018)<\/li>\n
  • Barbara E. Bierer, MD, MRCT Center<\/li>\n
  • Luther T. Clark, MD, Merck & Co., Inc.<\/li>\n
  • Milena Lolic, MD, U.S. Food and Drug Administration (August 2019 – August 2020)<\/li>\n
  • David H. Strauss, MD, Columbia University<\/li>\n
  • Junyang Wang, MSc, U.S. Food and Drug Administration (until August 2019)<\/li>\n
  • Sarah White, MPH, MRCT Center<\/li>\n
  • John Whyte, MD, MPH, U.S. Food and Drug Administration (until August 2018)<\/li>\n<\/ul>\n

    MRCT Center staff:<\/strong><\/p>\n

      \n
    • Carmen Aldinger, Administrative & Training Manager<\/li>\n
    • Hayat Ahmed, Project Manager<\/li>\n
    • Laura Meloney, Program Manager<\/li>\n
    • Joshua Smith-Sreen, Student Researcher<\/li>\n<\/ul>\n

      [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Principal workgroup members” tab_id=”1596393015499-45ce24a7-3b62″][vc_column_text]<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
      Name<\/strong><\/td>\nOrganization<\/strong><\/td>\n<\/tr>\n
      Maria Apostolaros<\/td>\nPharmaceutical Research and Manufacturers of America (PhRMA)<\/td>\n<\/tr>\n
      Abhijit Bapat*<\/td>\nNovartis<\/td>\n<\/tr>\n
      Stacey Bledsoe*<\/td>\nEli Lilly and Company<\/td>\n<\/tr>\n
      Shari Bodnoff*<\/td>\nNovartis<\/td>\n<\/tr>\n
      Racquel Bruton<\/td>\nBiogen<\/td>\n<\/tr>\n
      Elizabeth Cahn<\/td>\nCancer Connection<\/td>\n<\/tr>\n
      Li Chen<\/td>\nAmgen<\/td>\n<\/tr>\n
      Patrick Cullinan<\/td>\nTakeda, currently BlueBird Bio<\/td>\n<\/tr>\n
      Liza Dawson*<\/td>\nNational Institutes of Health (NIH)<\/td>\n<\/tr>\n
      Maria De Leon*<\/td>\nParkinson\u2019s Foundation<\/td>\n<\/tr>\n
      Theresa Devins<\/td>\nBoehringer Ingelheim, currently Regeneron Pharmaceuticals<\/td>\n<\/tr>\n
      Anthony Edmonds<\/td>\nTakeda<\/td>\n<\/tr>\n
      Rhonda Facile<\/td>\nClinical Data Interchange Standards Consortium (CDISC)<\/td>\n<\/tr>\n
      Rachael Fones<\/td>\nIQVIA<\/td>\n<\/tr>\n
      Laura Gordon*<\/td>\nInstitute for Advanced Clinical Trials for Children (iACT)<\/td>\n<\/tr>\n
      Anya Harry<\/td>\nGlaxoSmithKline (GSK)<\/td>\n<\/tr>\n
      Melissa Heidelberg<\/td>\nGenentech\/A Member of the Roche Group<\/td>\n<\/tr>\n
      Quita Highsmith<\/td>\nGenentech\/A Member of the Roche Group<\/td>\n<\/tr>\n
      Sharareh Hosseinzadeh<\/td>\nNovartis<\/td>\n<\/tr>\n
      Lloryn Hubbard*<\/td>\nGenentech\/A Member of the Roche Group<\/td>\n<\/tr>\n
      Anne Marie Inglis*<\/td>\nGlaxoSmithKline (GSK), currently Mallinckrodt Pharmaceuticals<\/td>\n<\/tr>\n
      Aarthi B. Iyer*<\/td>\nKinetiq, now Advarra<\/td>\n<\/tr>\n
      Becky Johnson*<\/td>\nIQVIA<\/td>\n<\/tr>\n
      Tesheia Johnson<\/td>\nYale School of Medicine<\/td>\n<\/tr>\n
      Jonathan Jackson*<\/td>\nMassachusetts General Hospital<\/td>\n<\/tr>\n
      Marcia Levenstein<\/td>\nVivli<\/td>\n<\/tr>\n
      Roberto Lewis<\/td>\nColumbia University<\/td>\n<\/tr>\n
      Eldrin Lewis<\/td>\nBrigham and Women\u2019s Hospital, currently Stanford University<\/td>\n<\/tr>\n
      Jianchang Lin*<\/td>\nTakeda<\/td>\n<\/tr>\n
      Erin Muhlbradt<\/td>\nNational Cancer Institute (NCI)<\/td>\n<\/tr>\n
      Isabela Niculae *<\/td>\nBiogen<\/td>\n<\/tr>\n
      Latha Palaniappan<\/td>\nStanford University<\/td>\n<\/tr>\n
      Claude Petit<\/td>\nBoehringer Ingelheim<\/td>\n<\/tr>\n
      Claire Pigula*<\/td>\nBiogen<\/td>\n<\/tr>\n
      Melissa Poindexter*<\/td>\nAdvances in Health<\/td>\n<\/tr>\n
      Nicole\u00a0Richie<\/td>\nGenentech\/ A Member of the Roche Group<\/td>\n<\/tr>\n
      Bryant (Abel) Riera*<\/td>\nPopulation Council<\/td>\n<\/tr>\n
      Suzanne M. Rivera<\/td>\nCase Western Reserve University<\/td>\n<\/tr>\n
      Frank W. Rockhold<\/td>\nDuke University<\/td>\n<\/tr>\n
      Ricardo Rojo*<\/td>\nPfizer<\/td>\n<\/tr>\n
      Rosanne Rotondo*<\/td>\nNovartis<\/td>\n<\/tr>\n
      Fabian Sandoval<\/td>\nEmerson Clinical Research Institute<\/td>\n<\/tr>\n
      Richard Sax*<\/td>\nIQVIA<\/td>\n<\/tr>\n
      Hollie Schmidt<\/td>\nAccelerated Cure Project for Multiple Sclerosis<\/td>\n<\/tr>\n
      Karlin Schroeder<\/td>\nParkinson’s\u00a0 Foundation<\/td>\n<\/tr>\n
      Mary Scroggins*<\/td>\nPinkie Hugs<\/td>\n<\/tr>\n
      Jessica Scott*<\/td>\nTakeda<\/td>\n<\/tr>\n
      Lana Skirboll<\/td>\nSanofi<\/td>\n<\/tr>\n
      Steven Snapinn<\/td>\nSeattle-Quilcene Biostatistics<\/td>\n<\/tr>\n
      Stacey Springs*<\/td>\nHarvard Medical School<\/td>\n<\/tr>\n
      Sara Tadesse-Bell<\/td>\nGenentech\/ A Member of the Roche Group<\/td>\n<\/tr>\n
      Ann Taylor*<\/td>\nColumbia University<\/td>\n<\/tr>\n
      Paul Underwood<\/td>\nBoston Scientific<\/td>\n<\/tr>\n
      Junyang Wang*<\/td>\nFood and Drug Administration (FDA)<\/td>\n<\/tr>\n
      Robert Winn*<\/td>\nUniversity of Illinois<\/td>\n<\/tr>\n
      Gerren Wilson*<\/td>\nGenentech\/ A Member of the Roche Group<\/td>\n<\/tr>\n
      Crispin Woolston<\/td>\nSanofi<\/td>\n<\/tr>\n
      Honghui Zhou*<\/td>\nJohnson & Johnson<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

       <\/p>\n

      *involvement limited in time[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Additional Reviewers” tab_id=”1596393387060-73116904-7077″][vc_column_text]<\/p>\n

        \n
      • Mark Barnes, Ropes & Gray and MRCT Center<\/li>\n
      • Maria DeLeon, Parkinson\u2019s Foundation<\/li>\n
      • David Hawks, National Council of Asian Pacific Islander Physicians and Alliance of Multicultural Physicians<\/li>\n
      • James H. Powell, Strategic Medical Associates<\/li>\n
      • Matthew Rotelli, Eli Lilly and Company<\/li>\n
      • William Tap, Memorial Sloan Kettering Cancer Center<\/li>\n<\/ul>\n

        [\/vc_column_text][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][\/vc_row]<\/p>\n<\/section>","protected":false},"excerpt":{"rendered":"

        [vc_row css=”.vc_custom_1617045318104{padding-right: 50px !important;padding-left: 50px !important;}”][vc_column][vc_empty_space][vc_column_text css=”.vc_custom_1596633942903{padding-bottom: 150px !important;}”]A 50+-member, international, multi-stakeholder workgroup convened by the Multi-Regional Clinical Trials Center of Brigham and Women\u2019s Hospital and Harvard University (MRCT Center) developed this Guidance Document and accompanying Toolkit.\u00a0 While every member contributed to the development of the Diversity Framework, the leadership of the MRCT Center is […]<\/p>\n","protected":false},"author":5,"featured_media":0,"parent":2724,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"template-sub.php","meta":{"footnotes":""},"class_list":["post-227","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/dev.mrctcenter.org\/diversity-in-clinical-research\/wp-json\/wp\/v2\/pages\/227"}],"collection":[{"href":"https:\/\/dev.mrctcenter.org\/diversity-in-clinical-research\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/dev.mrctcenter.org\/diversity-in-clinical-research\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/dev.mrctcenter.org\/diversity-in-clinical-research\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/dev.mrctcenter.org\/diversity-in-clinical-research\/wp-json\/wp\/v2\/comments?post=227"}],"version-history":[{"count":0,"href":"https:\/\/dev.mrctcenter.org\/diversity-in-clinical-research\/wp-json\/wp\/v2\/pages\/227\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/dev.mrctcenter.org\/diversity-in-clinical-research\/wp-json\/wp\/v2\/pages\/2724"}],"wp:attachment":[{"href":"https:\/\/dev.mrctcenter.org\/diversity-in-clinical-research\/wp-json\/wp\/v2\/media?parent=227"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}